Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 1
2016 1
2017 1
2018 1
2020 1
2021 3
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Discovery and development of varenicline for smoking cessation.
Jordan CJ, Xi ZX. Jordan CJ, et al. Expert Opin Drug Discov. 2018 Jul;13(7):671-683. doi: 10.1080/17460441.2018.1458090. Epub 2018 Mar 28. Expert Opin Drug Discov. 2018. PMID: 29587555 Free PMC article. Review.
Tobacco use causes one premature death every six seconds. Current smoking cessation aids include nicotine replacement therapies, bupropion, and varenicline. Although more than 70% of smokers express a desire to quit, fewer than 3% remain abstinent for more th …
Tobacco use causes one premature death every six seconds. Current smoking cessation aids include nicotine replacement therapie …
Smoking cessation medicines and e-cigarettes: a systematic review, network meta-analysis and cost-effectiveness analysis.
Thomas KH, Dalili MN, López-López JA, Keeney E, Phillippo D, Munafò MR, Stevenson M, Caldwell DM, Welton NJ. Thomas KH, et al. Health Technol Assess. 2021 Oct;25(59):1-224. doi: 10.3310/hta25590. Health Technol Assess. 2021. PMID: 34668482 Free article.
MAIN OUTCOME MEASURES: Effectiveness - continuous or sustained abstinence. Safety - serious adverse events, major adverse cardiovascular events and major adverse neuropsychiatric events. ...When the impact of major adverse neuropsychiatric …
MAIN OUTCOME MEASURES: Effectiveness - continuous or sustained abstinence. Safety - serious adverse events, major adverse cardiova …
Risk of neuropsychiatric and cardiovascular adverse events following treatment with varenicline and nicotine replacement therapy in the UK Clinical Practice Research Datalink: a case-cross-over study.
Thomas KH, Davies NM, Taylor AE, Taylor GMJ, Gunnell D, Martin RM, Douglas I. Thomas KH, et al. Addiction. 2021 Jun;116(6):1532-1545. doi: 10.1111/add.15338. Epub 2020 Dec 14. Addiction. 2021. PMID: 33197082 Free PMC article.
BACKGROUND AND AIMS: Varenicline and nicotine replacement therapy (NRT) are the most commonly used medications to quit smoking. Given their widespread use, monitoring adverse risks remains important. This study aimed to estimate the neuropsychiatric and ca …
BACKGROUND AND AIMS: Varenicline and nicotine replacement therapy (NRT) are the most commonly used medications to quit smoking …
Nicotine receptor partial agonists for smoking cessation.
Cahill K, Lindson-Hawley N, Thomas KH, Fanshawe TR, Lancaster T. Cahill K, et al. Cochrane Database Syst Rev. 2016 May 9;2016(5):CD006103. doi: 10.1002/14651858.CD006103.pub7. Cochrane Database Syst Rev. 2016. PMID: 27158893 Free PMC article. Updated. Review.
OBJECTIVES: To review the efficacy of nicotine receptor partial agonists, including varenicline and cytisine, for smoking cessation. SEARCH METHODS: We searched the Cochrane Tobacco Addiction Group's specialised register for trials, using the terms ('cytisine …
OBJECTIVES: To review the efficacy of nicotine receptor partial agonists, including varenicline and cytisine, for smoking c …
Abstinence Rate, Adverse Events and Withdrawal Symptoms after Varenicline Use and Predicting Factors of Smoking Abstinence: A Multicentre Single-State Study in Malaysia.
Choo SJ, Chang CT, Tangiisuran B, Latif MFA, Sanusi NA, Harun SN. Choo SJ, et al. Int J Environ Res Public Health. 2022 Jun 24;19(13):7757. doi: 10.3390/ijerph19137757. Int J Environ Res Public Health. 2022. PMID: 35805417 Free PMC article.
(1) Background: Varenicline is a widely prescribed agent in smoking cessation. However, the abstinence rate, the incidence of adverse events and withdrawal symptoms, have not been widely studied locally. This study aimed to determine the prevalence of …
(1) Background: Varenicline is a widely prescribed agent in smoking cessation. However, the abstinence rate, the incide …
Cardiovascular and neuropsychiatric risks of varenicline: a retrospective cohort study.
Kotz D, Viechtbauer W, Simpson C, van Schayck OC, West R, Sheikh A. Kotz D, et al. Lancet Respir Med. 2015 Oct;3(10):761-8. doi: 10.1016/S2213-2600(15)00320-3. Epub 2015 Sep 6. Lancet Respir Med. 2015. PMID: 26355008 Free PMC article.
BACKGROUND: Varenicline is an effective pharmacotherapy to aid smoking cessation. However, its use is limited by continuing concerns about possible associated risks of serious adverse cardiovascular and neuropsychiatric events. The aim of …
BACKGROUND: Varenicline is an effective pharmacotherapy to aid smoking cessation. However, its use is limited by contin …
Cardiovascular and neuropsychiatric safety of varenicline and bupropion compared with nicotine replacement therapy for smoking cessation: study protocol of a retrospective cohort study using the QResearch general practice database.
Kotz D, Simpson C, Viechtbauer W, van Schayck OC, West R, Sheikh A. Kotz D, et al. BMJ Open. 2014 Aug 28;4(8):e005281. doi: 10.1136/bmjopen-2014-005281. BMJ Open. 2014. PMID: 25168037 Free PMC article.
The safety profile of varenicline was initially established using standard approaches to pharmacovigilance, but postmarketing reports have raised concerns about a possible association between the use of varenicline and cardiovascular and neuropsychiatric …
The safety profile of varenicline was initially established using standard approaches to pharmacovigilance, but postmarketing reports …
Cardiovascular and neuropsychiatric risks of varenicline and bupropion in smokers with chronic obstructive pulmonary disease.
Kotz D, Viechtbauer W, Simpson CR, van Schayck OCP, West R, Sheikh A. Kotz D, et al. Thorax. 2017 Oct;72(10):905-911. doi: 10.1136/thoraxjnl-2017-210067. Epub 2017 May 4. Thorax. 2017. PMID: 28473506 Free article.
BACKGROUND: Varenicline and bupropion are effective smoking cessation treatments, but there are concerns about their safety in smokers with COPD. OBJECTIVE: To investigate whether varenicline and bupropion are associated with serious adverse cardiov …
BACKGROUND: Varenicline and bupropion are effective smoking cessation treatments, but there are concerns about their sa …
Interventions for Tobacco Cessation in Adults, Including Pregnant Women: An Evidence Update for the U.S. Preventive Services Task Force.
Patnode CD, Henderson JT, Melnikow J, Coppola EL, Durbin S, Thomas R. Patnode CD, et al. Rockville (MD): Agency for Healthcare Research and Quality (US); 2021 Jan. Report No.: 20-05264-EF-1. Rockville (MD): Agency for Healthcare Research and Quality (US); 2021 Jan. Report No.: 20-05264-EF-1. PMID: 33523610 Free Books & Documents. Review.
Although less evidence is available, certain medications such as nortriptyline and cytisine used for tobacco cessation have shown potential benefits. None of the drugs were associated with serious adverse events, including major cardiovascular adverse even …
Although less evidence is available, certain medications such as nortriptyline and cytisine used for tobacco cessation have shown pot …